1
|
Rane VP, Ahirrao VK, Patil KR, Jadhav AB, More KB, Yeole RD. Liquid Chromatographic Separation and Thermodynamic Investigation of Ethyl Nipecotate Enantiomers on Immobilized Amylose-Based Chiral Stationary Phase. J Chromatogr Sci 2019; 57:815-820. [DOI: 10.1093/chromsci/bmz065] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2018] [Revised: 06/24/2019] [Accepted: 07/07/2019] [Indexed: 11/13/2022]
Abstract
Abstract
Ethyl nipecotate enantiomers are widely used as chiral building blocks in the synthesis of drug substances. An efficient and economic chiral high-performance liquid chromatographic method for determination of enantiomeric purity of ethyl nipecotate is developed and validated. Chiral separation was achieved on immobilized amylose-based stationary phase using a mixture of n-hexane: ethanol: diethylamine (80:20:0.1, v/v/v) as mobile phase. Resolution between R-(-)-ethyl nipecotate (REN) and S-(+)-ethyl nipecotate (SEN) peaks was found to be 3.59. The detector response of SEN exhibited an excellent linearity over the concentration range of 4.5–120 μg mL−1. The limit of detection and limit of quantification for SEN were 0.016 and 0.045 μg and REN were 0.015 and 0.043 μg, respectively. The influence of column oven temperatures on chiral retention and separation was studied in the range of 25°C to 50°C; the thermodynamic parameters ΔH°, ΔS° and ΔG° were evaluated from van’t Hoff plots and used to explain the strength of interaction between analyte and stationary phase.
Collapse
Affiliation(s)
- Vipul P Rane
- Wockhardt Research Centre, D-4, MIDC, Chikalthana, Aurangabad, 431006, India
| | - Vinod K Ahirrao
- Wockhardt Research Centre, D-4, MIDC, Chikalthana, Aurangabad, 431006, India
| | - Kiran R Patil
- Wockhardt Research Centre, D-4, MIDC, Chikalthana, Aurangabad, 431006, India
| | - Arjun B Jadhav
- Wockhardt Research Centre, D-4, MIDC, Chikalthana, Aurangabad, 431006, India
| | - Kiran B More
- Wockhardt Research Centre, D-4, MIDC, Chikalthana, Aurangabad, 431006, India
| | - Ravindra D Yeole
- Wockhardt Research Centre, D-4, MIDC, Chikalthana, Aurangabad, 431006, India
| |
Collapse
|
4
|
Li J, Chen J, Zhang L, Wang F, Gui C, Zhang L, Qin Y, Xu Q, Liu H, Nan F, Shen J, Bai D, Chen K, Shen X, Jiang H. One novel quinoxaline derivative as a potent human cyclophilin A inhibitor shows highly inhibitory activity against mouse spleen cell proliferation. Bioorg Med Chem 2006; 14:5527-34. [PMID: 16682211 PMCID: PMC7126670 DOI: 10.1016/j.bmc.2006.04.026] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2006] [Revised: 04/21/2006] [Accepted: 04/21/2006] [Indexed: 01/31/2023]
Abstract
Cyclophilin A (CypA) is a ubiquitous cellular enzyme playing critical roles in many biological processes, and its inhibitor has been reported to have potential immunosuppressive activity. In this work, we reported a novel quinoxaline derivative, 2,3-di(furan-2-yl)-6-(3-N,N-diethylcarbamoyl-piperidino)carbonylamino quinoxaline (DC838, 3), which was confirmed to be a potent inhibitor against human CypA. By using the surface plasmon resonance (SPR) and fluorescence titration techniques, the kinetic analysis of CypA/DC838 interaction was quantitatively performed. CypA peptidyl prolyl cis–trans isomerase (PPIase) activity inhibition assay showed that DC838 demonstrated highly CypA PPIase inhibitory activity. In vivo assay results showed that DC838 could inhibit mouse spleen cell proliferation induced by concanavalin A (Con A). Molecular docking simulation further elucidated the specific DC838 binding to CypA at the atomic level. The current work should provide useful information in the discovery of immunosuppressor based on CypA inhibitor.
Collapse
Affiliation(s)
- Jian Li
- Drug Discovery and Design Centre, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 201203, China
| | - Jing Chen
- Drug Discovery and Design Centre, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 201203, China
| | - Li Zhang
- Drug Discovery and Design Centre, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 201203, China
| | - Feng Wang
- Drug Discovery and Design Centre, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 201203, China
| | - Chunshan Gui
- Drug Discovery and Design Centre, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 201203, China
| | - Li Zhang
- State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, 22 Han Kou Road, Nanjing 210093, China
| | - Yu Qin
- State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, 22 Han Kou Road, Nanjing 210093, China
| | - Qiang Xu
- State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, 22 Han Kou Road, Nanjing 210093, China
| | - Hong Liu
- Drug Discovery and Design Centre, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 201203, China
| | - Fajun Nan
- Drug Discovery and Design Centre, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 201203, China
| | - Jingkang Shen
- Drug Discovery and Design Centre, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 201203, China
| | - Donglu Bai
- Drug Discovery and Design Centre, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 201203, China
| | - Kaixian Chen
- Drug Discovery and Design Centre, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 201203, China
| | - Xu Shen
- Drug Discovery and Design Centre, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 201203, China
- School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
- Corresponding authors. Tel./fax: +86 21 50806918 (X.S.).
| | - Hualiang Jiang
- Drug Discovery and Design Centre, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 201203, China
- School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
- Corresponding authors. Tel./fax: +86 21 50806918 (X.S.).
| |
Collapse
|
5
|
Moher ED, Tripp AE, Creemer LC, Vicenzi JT. Development of an Efficient Synthesis for a Nipecotate-Containing Immunopotentiator. Org Process Res Dev 2004. [DOI: 10.1021/op049941c] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Eric D. Moher
- Eli Lilly and Company, Chemical Product Research and Development Division, Indianapolis, Indiana 46285, U.S.A., and Elanco Animal Health Research and Development, Greenfield, Indiana 46140, U.S.A
| | - Allie E. Tripp
- Eli Lilly and Company, Chemical Product Research and Development Division, Indianapolis, Indiana 46285, U.S.A., and Elanco Animal Health Research and Development, Greenfield, Indiana 46140, U.S.A
| | - Lawrence C. Creemer
- Eli Lilly and Company, Chemical Product Research and Development Division, Indianapolis, Indiana 46285, U.S.A., and Elanco Animal Health Research and Development, Greenfield, Indiana 46140, U.S.A
| | - Jeffrey T. Vicenzi
- Eli Lilly and Company, Chemical Product Research and Development Division, Indianapolis, Indiana 46285, U.S.A., and Elanco Animal Health Research and Development, Greenfield, Indiana 46140, U.S.A
| |
Collapse
|
8
|
Guo Z, Zheng X, Thompson W, Dugdale M, Gollamudi R. New carbamoylpiperidines as human platelet aggregation inhibitors. Bioorg Med Chem 2000; 8:1041-58. [PMID: 10882016 DOI: 10.1016/s0968-0896(00)00033-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
A series of 3-carbamoylpiperidines (nipecotamides) are designed, synthesized and tested for their inhibitory action against adenosine diphosphate (ADP)-induced aggregation of human platelets. A structure-activity analysis of the bis(nipecotamido)aralkane type showed that a substituent on the piperidine ring should preferably be an amide and that the electronegativity of the carbonyl oxygen and the orientation of the amide group affected activities. Based on the knowledge of factors influencing platelet activation and aggregation, a nitric ester moiety which could release nitric oxide (NO) in situ, is incorporated into the nipecotamide structure. These compounds exhibit increased activity compared to those having no -ONO2 function. They also show stereoselectivity, with the meso isomer being approximately twice as potent as the synthetic diastereomeric mixture. Replacement of the -ONO2 function with hydroxyl, ester or alkyl groups considerably diminishes aggregation-inhibitory potential. Nipecotamides are shown here to inhibit the basal and collagen-induced rise in platelet inositol trisphosphate (IP3) levels, as well as phosphoinositide turnover. A comprehensive mechanism of action is proposed taking earlier results into consideration.
Collapse
Affiliation(s)
- Z Guo
- Department of Pharmaceutical Sciences, The University of Tennessee, Memphis 38163, USA
| | | | | | | | | |
Collapse
|
9
|
Chung YJ, Huck BR, Christianson LA, Stanger HE, Krauthäuser S, Powell DR, Gellman SH. Stereochemical Control of Hairpin Formation in β-Peptides Containing Dinipecotic Acid Reverse Turn Segments. J Am Chem Soc 2000. [DOI: 10.1021/ja993416p] [Citation(s) in RCA: 113] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Yong Jun Chung
- Contribution from the Department of Chemistry, University of Wisconsin, Madison, Wisconsin 53706
| | - Bayard R. Huck
- Contribution from the Department of Chemistry, University of Wisconsin, Madison, Wisconsin 53706
| | - Laurie A. Christianson
- Contribution from the Department of Chemistry, University of Wisconsin, Madison, Wisconsin 53706
| | - Heather E. Stanger
- Contribution from the Department of Chemistry, University of Wisconsin, Madison, Wisconsin 53706
| | - Susanne Krauthäuser
- Contribution from the Department of Chemistry, University of Wisconsin, Madison, Wisconsin 53706
| | - Douglas R. Powell
- Contribution from the Department of Chemistry, University of Wisconsin, Madison, Wisconsin 53706
| | - Samuel H. Gellman
- Contribution from the Department of Chemistry, University of Wisconsin, Madison, Wisconsin 53706
| |
Collapse
|
10
|
Han G, Bannerman D, Handa RK, Dillingham EO, Lawrence WH, Gollamudi R. Antiplatelet effects of R,S-(meso)-alpha, alpha'-bis[3-(N,N-diethylcarbamoyl) piperidino]-p-xylene ex vivo in the dog and in vivo in the mouse. GENERAL PHARMACOLOGY 1997; 28:617-21. [PMID: 9147034 DOI: 10.1016/s0306-3623(96)00272-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
1. The nipecotamide alpha,alpha'-bis[3-(N,N-diethylcarbamoyl)piperidino]-p-xylene (A-1) is a platelet aggregation inhibitor. The meso diastereomer A-1c is superior in potency and duration to the synthetic diastereomeric mixture consisting of the R,R-, S,S-, and R,S- (meso) isomers in inhibiting collagen-induced platelet aggregation ex vivo in the dog. 2. A-1c also is more potent and longer acting than A-1 in protecting mice from collagen+epinephrine-induced thromboembolic death. 3. The mechanism of antiplatelet action of this compound appears to be related to its ability to prevent agonist-induced inhibition of platelet cyclic adenosine monophosphate (cAMP) levels.
Collapse
Affiliation(s)
- G Han
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee, Memphis 38163, USA
| | | | | | | | | | | |
Collapse
|